Effect of early octreotide administration on the development of esophageal varices in cirrhotic rats

• Published in: Hepatology research Vol. 29; no. 2; p. 104
• Main Authors: Ballas, Konstantinos D., Tzioufa-Asimakopoulou, Valentine, Marakis, George, Alatsakis, Michael B., Papavasiliou, Athanassios V., Rafailidis, Savvas, Sakadamis, Athanassios K.
• Format: Journal Article
• Language: English
• Published: Netherlands 01.06.2004
• ISSN: 1386-6346; 1872-034X
• DOI: 10.1016/j.hepres.2004.02.016

This study was conducted to investigate the effect of chronic octreotide administration on the development of esophageal varices in rats being at the early stages of carbon tetrachloride-induced cirrhosis. For the development of liver cirrhosis and esophageal varices 96 rats underwent ligation of left adrenal vein followed by phenobarbital and carbon tetrachloride administration. After 2 weeks of carbon tetrachloride administration, rats were randomly separated into three groups. Chronic octreotide administration started in group A, normal saline in group B, while 32 rats consisted control group. Haemodynamic studies and morphometric analysis of the lower esophagus were performed 2 weeks after complete induction of cirrhosis. Total submucosal vessel area, mean cross-sectional area of submucosal vessels, percentage of submucosa occupied by vessels, the area of the most dilated submucosal vessel as well as the number of submucosal vessels were studied. Octreotide administration induced a significant ( [Formula: see text] ) decrease of portal vein pressure. Morphometric analysis revealed a significant reduction ( [Formula: see text] ) in octreotide-treated rats of both "total submucosal vessel area" and area of "the most dilated submucosal vessel". Chronic octreotide administration partially prevented rats from the development of esophageal varices. Octreotide-treated rats were found to have a less pronounced dilatation of submucosal veins compared to placebo-treated group rats. We believe that this effect was mainly due to the decrease of portal vein pressure induced by chronic octreotide administration.